2.0257
9.01%
-0.1943
Precedente Chiudi:
$2.22
Aprire:
$2.23
Volume 24 ore:
706.79K
Relative Volume:
0.71
Capitalizzazione di mercato:
$260.65M
Reddito:
$36.86M
Utile/perdita netta:
$-171.67M
Rapporto P/E:
-0.993
EPS:
-2.04
Flusso di cassa netto:
$-171.05M
1 W Prestazione:
-19.84%
1M Prestazione:
-3.81%
6M Prestazione:
-22.90%
1 anno Prestazione:
+27.85%
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Nome
Mersana Therapeutics Inc
Settore
Industria
Telefono
617-498-0020
Indirizzo
840 MEMORIAL DRIVE, CAMBRIDGE
Confronta MRSN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
MRSN | 2.02 | 260.65M | 36.86M | -171.67M | -171.05M | -2.04 |
VRTX | 450.61 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 749.05 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.41 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.82 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-12-04 | Aggiornamento | Citigroup | Neutral → Buy |
2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
2023-07-27 | Downgrade | BTIG Research | Buy → Neutral |
2023-07-27 | Downgrade | Citigroup | Buy → Neutral |
2023-07-27 | Downgrade | Guggenheim | Buy → Neutral |
2023-07-27 | Downgrade | JP Morgan | Neutral → Underweight |
2023-07-27 | Downgrade | Truist | Buy → Hold |
2023-07-27 | Downgrade | Wedbush | Outperform → Neutral |
2023-06-16 | Downgrade | JP Morgan | Overweight → Neutral |
2023-06-15 | Iniziato | Guggenheim | Buy |
2023-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
2023-01-20 | Iniziato | Citigroup | Buy |
2022-11-21 | Iniziato | Truist | Buy |
2021-10-15 | Ripresa | BTIG Research | Buy |
2021-08-30 | Iniziato | H.C. Wainwright | Buy |
2021-03-31 | Iniziato | Credit Suisse | Neutral |
2020-12-03 | Iniziato | Stifel | Buy |
2020-09-29 | Ripresa | JP Morgan | Neutral |
2020-04-29 | Iniziato | BTIG Research | Buy |
2020-01-21 | Reiterato | H.C. Wainwright | Buy |
2019-03-11 | Downgrade | JP Morgan | Neutral → Underweight |
2018-11-14 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
2018-05-08 | Iniziato | Robert W. Baird | Outperform |
2018-03-19 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie
This Particular Biotech Stock Is Soaring On Two Key Announcements - MSN
Mersana Therapeutics (STU:0M4) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Mersana Therapeutics Q3 2024 Earnings Preview - MSN
16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE - Defense World
Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World
Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World
Wedbush Expects Increased Earnings for Mersana Therapeutics - MarketBeat
FY2024 Earnings Estimate for MRSN Issued By Leerink Partnrs - MarketBeat
Mersana Therapeutics transferred with Buy rating at Citi - MSN
MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com
Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com
Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at Citigroup - MarketBeat
MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World
MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Free Cash Flow : $-95.57 Mil (TTM As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.63 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com
MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Net Income From Continuing Operations : $-104.77 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow from Operations : $-132.56 Mil (TTM As of Jun. 2024) - GuruFocus.com
Balyasny Asset Management L.P. Acquires New Stake in Mersana The - GuruFocus.com
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript - Insider Monkey
Rivian, Mersana Therapeutics, MicroStrategy (MSTR) and Honest Company Among Strong Movers in Premarket Trades - TopNews India
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials By Investing.com - Investing.com UK
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
FANG Index (FGU25) Quote - The Globe and Mail
Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates - MarketWatch
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Mersana Therapeutics (MRSN) Q3 2024 Earnings: EPS Loss of $0.09 Beats Estimates, Revenue Surges to $12.6M - GuruFocus.com
Mersana Therapeutics Reports Progress in Cancer Treatments - TipRanks
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - GlobeNewswire
Mersana Therapeutics, Inc. Provides Business Update - Marketscreener.com
Earnings Preview For Mersana Therapeutics - Benzinga
Mersana Therapeutics presents new data on XMT-2056 - BioWorld Online
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Price Target from Brokerages - Defense World
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly? - Simply Wall St
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $6.00 - MarketBeat
Mersana Therapeutics Inc Azioni (MRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):